This is the authors' abstract. We don't add key points for this paper.
This cross-sectional study describes and historically benchmarks Medicare Part D coverage in 2019 and 2023 for the first 10 drugs selected for negotiation.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Patterson et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: